ATG4B and leukemia: Similarly, compared to WT AML model mice, ATG4B‐deficient AML model mice exhibited a markedly decreased leukemia burden and prolonged survival even after serial transplantation (Figure 7E,H,K; Figure S6D,E, Supporting Information).